Kyowa Kirin

Kyowa Kirin to acquire Orchard Therapeutics for $478 million
Kyowa Kirin to acquire Orchard Therapeutics for $478 million
Reuters
Kyowa Kirin
Orchard Therapeutics
M&A
Flag link:
Kyowa Kirin Opens New Jersey Headquarters
Kyowa Kirin Opens New Jersey Headquarters
BioSpace
Kyowa Kirin
New Jersey
headquarters
Flag link:
After FDA setback, MEI, Kyowa confirm phase 2 efficacy with Japanese blood cancer data drop
After FDA setback, MEI, Kyowa confirm phase 2 efficacy with Japanese blood cancer data drop
Fierce Biotech
Kyowa Kirin
MEI Pharma
zandelisib
clinical trials
non-Hodgkin lymphoma
Flag link:
If at first... pharma’s most drawn-out development timelines revealed
If at first... pharma’s most drawn-out development timelines revealed
EP Vantage
Kyowa Kirin
Takeda
Eiger BioPharmaceuticals
AstraZeneca
Teva Pharmaceutical
Bavarian Nordic
Halozyme
Novartis
MannKind
drug development
Flag link:
Weeks after starting, Amgen flashes yellow light on PhIII of $400M eczema bet
Weeks after starting, Amgen flashes yellow light on PhIII of $400M eczema bet
Endpoints
Amgen
Kyowa Kirin
clinical trials
AMG 451
atopic dermatitis
Flag link:
Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s
Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s
Pharmaforum
Kyowa Kirin
KW-6356
clinical trials
Parkinson's Disease
Flag link:
Kyowa Kirin Could Sell $1B in Assets as it Advances PI3K Inhibitor
Kyowa Kirin Could Sell $1B in Assets as it Advances PI3K Inhibitor
BioSpace
Kyowa Kirin
Flag link:
Ardelyx amends license deal with Kyowa Kirin for tenapanor
Ardelyx amends license deal with Kyowa Kirin for tenapanor
Pharmaceutical Business Review
Ardelyx
Kyowa Kirin
tenapanor
Flag link:
FDA Concerns Over PI3K Inhibitors Snag MEI Pharma, Kyowa Kirin
FDA Concerns Over PI3K Inhibitors Snag MEI Pharma, Kyowa Kirin
BioSpace
MEI Pharma
Kyowa Kirin
FDA
zandelisib
PI3k inhibitor
Flag link:
Amgen reveals midphase eczema data behind its $400M bet
Amgen reveals midphase eczema data behind its $400M bet
Fierce Biotech
Amgen
Kyowa Kirin
clinical trials
eczema
antibodies
Flag link:
Amgen follows Sanofi into a new dermatitis mechanism
Amgen follows Sanofi into a new dermatitis mechanism
EP Vantage
Amgen
Sanofi
atopic dermatitis
Ichnos
KHK4083
Kyowa Kirin
Flag link:
Ultragenyx earns 2 rare disease drug approvals—and a validated commercial strategy
Ultragenyx earns 2 rare disease drug approvals—and a validated commercial strategy
Fierce Pharma
Ultragenyx
FDA
Crysvita
tumor-induced osteomalacia
Kyowa Kirin
Dojolvi
Flag link:
GSK’s kidney disease anemia drug approved in Japan, taking on Astellas’ rival
GSK’s kidney disease anemia drug approved in Japan, taking on Astellas’ rival
Pharmaforum
GSK
anemia
chronic kidney disease
daprodustat
Japan
Astellas
Kyowa Kirin
Flag link:
Ultragenyx's Crysvita scores FDA nod in 2nd ultra-rare bone disorder
Ultragenyx's Crysvita scores FDA nod in 2nd ultra-rare bone disorder
Fierce Pharma
Ultragenyx
Kyowa Kirin
Crysvita
FDA
tumor-induced osteomalacia
Flag link: